By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
Gauging the Upsides and downsides of Visas: A Complete Aide - 2This Underrated Italian City Boasts Indulgent Food & Captivating Views For A Romantic Escape
- 3Sheinelle Jones will cohost fourth hour of 'Today' with Jenna Bush Hager: Here's what to know about her
- 4Zelensky sees new Russian attack threat from Belarus
- 5Top 10 Arising Advances That Will Shape What's in store
- Find the Interesting Universe of Computerized reasoning: the Capability of man-made intelligence
- Scientists have found an alarming environmental impact of vast data centers
- IDF struck Iran's largest petrochemical plant, second facility hit in two days, Katz confirms
- Manual for extravagance SUVs for seniors
- Flourishing as a Charitable Pioneer: Individual Encounters in Generosity
- We analyzed Philly street scenes and identified signs of gentrification using machine learning trained on longtime residents’ observations
- Figure out How to Clean and Really focus on Your Lab Jewel
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- The Ascent of Rousing Pioneers Who Formed History
